S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Prevail Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 01/22/2021)
Today's Range
Now: $23.00
50-Day Range
MA: $23.01
52-Week Range
Now: $23.00
Average Volume955,800 shs
Market Capitalization$787.66 million
P/E RatioN/A
Dividend YieldN/A
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.
Prevail Therapeutics logo


Lilly Closes Acquisition Of Prevail Therapeutics
January 22, 2021 |  nasdaq.com
Notable Wednesday Option Activity: PRVL, IP, LB
December 23, 2020 |  nasdaq.com
Lilly to Pick up Prevail
December 15, 2020 |  marketwatch.com
What Eli Lilly Gets From Its Most Recent Acquisition
December 15, 2020 |  247wallst.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:PRVL
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$4.85 per share


Net Income$-63,190,000.00


Market Cap$787.66 million
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.34 out of 5 stars

Medical Sector

702nd out of 1,972 stocks

Biological Products, Except Diagnostic Industry

96th out of 177 stocks

Analyst Opinion: 2.1Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Receive PRVL News and Ratings via Email

Sign-up to receive the latest news and ratings for PRVL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Prevail Therapeutics (NASDAQ:PRVL) Frequently Asked Questions

Is Prevail Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prevail Therapeutics in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Prevail Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRVL, but not buy additional shares or sell existing shares.
View analyst ratings for Prevail Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Prevail Therapeutics?

Wall Street analysts have given Prevail Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Prevail Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Prevail Therapeutics' next earnings date?

Prevail Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Prevail Therapeutics

How were Prevail Therapeutics' earnings last quarter?

Prevail Therapeutics Inc. (NASDAQ:PRVL) posted its earnings results on Friday, November, 13th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.09.
View Prevail Therapeutics' earnings history

What price target have analysts set for PRVL?

9 brokerages have issued 12 month price objectives for Prevail Therapeutics' stock. Their forecasts range from $20.00 to $26.00. On average, they expect Prevail Therapeutics' stock price to reach $23.50 in the next year. This suggests a possible upside of 2.2% from the stock's current price.
View analysts' price targets for Prevail Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Prevail Therapeutics' key executives?

Prevail Therapeutics' management team includes the following people:
  • Dr. Asa Abeliovich M.D., Ph.D., Founder, Pres, CEO & Director (Age 56, Pay $737.47k)
  • Dr. Yong Dai Ph.D., Chief Technology Officer (Age 49, Pay $450.62k)
  • Dr. Jeffrey Sevigny M.D., Chief Medical Officer (Age 51, Pay $593k)
  • Dr. Brett Kaplan M.D., CFO & Sec. (Age 46)
  • Ms. Kira M. Schwartz, Gen. Counsel
  • Ms. Emily Minkow, Chief Bus. Officer (Age 37)
  • Dr. Franz F. Hefti Ph.D., Chief Devel. Officer (Age 72)

Who are some of Prevail Therapeutics' key competitors?

What other stocks do shareholders of Prevail Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prevail Therapeutics investors own include Sorrento Therapeutics (SRNE), Alector (ALEC), Gossamer Bio (GOSS), Editas Medicine (EDIT), Harpoon Therapeutics (HARP), Atreca (BCEL), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO) and Stoke Therapeutics (STOK).

When did Prevail Therapeutics IPO?

(PRVL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Prevail Therapeutics' stock symbol?

Prevail Therapeutics trades on the NASDAQ under the ticker symbol "PRVL."

Who are Prevail Therapeutics' major shareholders?

Prevail Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.60%), Alpine Associates Management Inc. (2.50%), Alyeska Investment Group L.P. (1.74%), Alyeska Investment Group L.P. (1.74%), GABELLI & Co INVESTMENT ADVISERS INC. (0.60%) and Gabelli Funds LLC (0.53%). Company insiders that own Prevail Therapeutics stock include Acquisition Corp Tyto and Carl L Gordon.
View institutional ownership trends for Prevail Therapeutics

Which major investors are selling Prevail Therapeutics stock?

PRVL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, JPMorgan Chase & Co., Squarepoint Ops LLC, Barclays PLC, Strs Ohio, GSA Capital Partners LLP, and Nuveen Asset Management LLC.
View insider buying and selling activity for Prevail Therapeutics
or view top insider-selling stocks.

Which major investors are buying Prevail Therapeutics stock?

PRVL stock was acquired by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Alyeska Investment Group L.P., Alyeska Investment Group L.P., GABELLI & Co INVESTMENT ADVISERS INC., Gabelli Funds LLC, Glazer Capital LLC, Credit Suisse AG, and Water Island Capital LLC. Company insiders that have bought Prevail Therapeutics stock in the last two years include Acquisition Corp Tyto, and Carl L Gordon.
View insider buying and selling activity for Prevail Therapeutics
or or view top insider-buying stocks.

What is Prevail Therapeutics' stock price today?

One share of PRVL stock can currently be purchased for approximately $23.00.

How much money does Prevail Therapeutics make?

Prevail Therapeutics has a market capitalization of $787.66 million. The company earns $-63,190,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis.

How many employees does Prevail Therapeutics have?

Prevail Therapeutics employs 66 workers across the globe.

What is Prevail Therapeutics' official website?

The official website for Prevail Therapeutics is www.prevailtherapeutics.com.

Where are Prevail Therapeutics' headquarters?

Prevail Therapeutics is headquartered at 430 East 29th Street Suite 1520, New York NY, 10016.

How can I contact Prevail Therapeutics?

Prevail Therapeutics' mailing address is 430 East 29th Street Suite 1520, New York NY, 10016. The company can be reached via phone at 917-336-9310 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.